摘要
探讨异博定对卵巢癌细胞多药耐药基因MDR1表达产物P糖蛋白 (P170 )和促进化疗药物诱使癌细胞增加凋亡因子表达的影响。从 48例首次手术及 17例复发卵巢癌患者腹水中提取富含癌细胞的悬液 ,应用三种荧光单克隆抗体P170 .CD95及APO2 .7标记 ,经流式细胞仪检测。结果 :应用异博定化疗后癌细胞CD95及Apo2 .7表达含量均高于对照组 ;异博定对癌细胞P170表达含量无明显影响 ;复发组癌细胞P170表达含量显著高于初发手术组 ;化疗可使外周血淋巴细胞CD95及Apo2 .7表达含量增加。本研究提示异博定具有加强化疗药物增加卵巢癌细胞增加凋亡的作用 ,特别是对耐药性患者具有重要的临床应用价值。
To explore the role of calcium antagonist-VPL for the cellular Mdr1 expression product (P170) and apotosis of ovarian carcinoma in chemotherapy.The samples of ascites cancer cells(ACC)were collected in forty-eight primary and seventeen recurred ovarian cancers, immunologically marked by three kinds of fluorescent monoantibodies-P170, CD95 and Apo2.7 then determined by flow cytometry.The results were:(1)VPL was not effected the P170 expression contents of ACC;(2)The CD95 and Apo2.7 expression contents of ACC were statistically more improved in VPL group than in Non-VPL one(P<0.05);(3)the p170 contents were statistically more improved in recurred group than that of in primary one (P<0.05);The CD95 and Apo2.7 contents of peripheral lymphocyte were also improved in chemotherapy joined by VPL.This suggested the calcium antagonist-VPL could obviously improve the apoptotic rate of ACC in ovarian carcian carcinoma in chemotherapy and has important clinical significance.
出处
《中国优生与遗传杂志》
2000年第3期37-39,共3页
Chinese Journal of Birth Health & Heredity
关键词
卵巢肿瘤
异博定
凋亡
药物疗法
Ovarian tumor
Apoptosis
CD95.Apo2.7
Calcium antagonist
Chemotheray.
